| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6465463 | AZURITY | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
Sep, 2020
(3 years ago) | |
| US6784177 | AZURITY | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
Sep, 2020
(3 years ago) | |
Bidil is owned by Azurity.
Bidil contains Hydralazine Hydrochloride; Isosorbide Dinitrate.
Bidil has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Bidil are:
- US6465463
- US6784177
Bidil was authorised for market use on 23 June, 2005.
Bidil is available in tablet;oral dosage forms.
Bidil can be used as method of treatment of heart failure.
The generics of Bidil are possible to be released after 08 September, 2020.
Drugs and Companies using HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE ingredient
Market Authorisation Date: 23 June, 2005
Treatment: Method of treatment of heart failure
Dosage: TABLET;ORAL
More Information on Dosage
BIDIL family patents
